Lebanon Pharmaceuticals and Healthcare Report Q3 2013:Life Sciences Market Research Reports

Life Sciences Market Research Reports

Lebanon Pharmaceuticals and Healthcare Report Q3 2013 May 29th 2013, 00:00 BMI View: Although Lebanon’s pharmaceutical market will remain largely valued by patented medicines consumption, we expect a swifter uptake in generic medicines over the 2012-2022 period. However, this generic drug uptake is jeopardised by the ongoing Syrian civil war. Syria’s civil unrest will continue to hinder pharmaceutical trade relations between Lebanon’s import-dependent medicines market and key drugmakers in Israel and Jordan, namely Teva Pharmaceuticals and Hikma Pharmaceuticals. Rising Lebanese political and economic instability, will also negatively impact consumption of locally produced and imported medicines. Headline Expenditure Projections ? Pharmaceuticals: LBP1,956bn (US$1.30bn) in 2012 to LBP2,038bn (US$1.36bn) in 2013; +4.2% in … Order / Buy a copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=98770. Complete report details with Table of Contents and more @ http://www.rnrmarketresearch.com/lebanon-pharmaceuticals-and-healthcare-report-q3-2013-market-report.html.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions